BSE · 526075
Rekvina Laboratories Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Shareholding
As of 2026-06-30
- Promoter41.3%
- Public58.7%
2,465 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 6.91× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — GSM · GSM 0 · ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
- Reported zero revenue in 4 of the last 8 disclosed periods.
- 52-week range spans 6.91× (₹6.75 to ₹46.65) — an unusually wide band.
Peer comparison
Trading · ranked #393 of 666 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Enterprises Limited | ₹3,93,459 Cr | 24.35 | 4.83 | 3.42% | 9.3% |
| Avenue Supermarts Limited | ₹2,50,959 Cr | 381.38 | 10.26 | 12.14% | 4.32% |
| Trent Ltd. | ₹1,60,247 Cr | 266.89 | 22.94 | 24.62% | 8.57% |
| FSN E-Commerce Ventures Ltd. | ₹93,790 Cr | 1212.96 | 65.21 | 13.87% | 1.99% |
| Vishal Mega Mart Limited | ₹50,703 Cr | 300.67 | 6.82 | 11.32% | 6.61% |
| Premier Energies Limited | ₹47,038 Cr | 102.19 | 10.91 | 35.05% | 19.3% |
| Aegis Logistics Limited | ₹45,019 Cr | 109.72 | 7.44 | 14.83% | 10.78% |
| Aditya Infotech Limited | ₹40,364 Cr | 238.34 | 21.5 | 19.61% | 8.72% |
| Redington Limited | ₹22,472 Cr | 57.38 | 2.21 | 14.67% | 1.25% |
| Honasa Consumer Limited | ₹14,620 Cr | 210.96 | 10.36 | 14.16% | 8.36% |
| Rekvina Laboratories Ltd.(this company) | ₹15 Cr | — | 0 | 20.74% | -19.69% |
AI analysis
AI-generated · google/gemini-2.5-flashRekvina Laboratories Ltd. is listed on the Indian markets with a market capitalization of Rs 16 Cr. The company reported a negative Book Value of Rs -2.03 and a negative Return on Capital Employed (ROCE) of -104.17%. The public shareholding as of March 31, 2026, was 58.70%, with promoter holding at 41.30%. The company is currently under surveillance measures, including GSM and ESM.
Positives
- +The debt-to-equity ratio is 0, indicating no outstanding debt.
- +Promoter pledge is 0, suggesting no shares are pledged by the promoters.
Negatives
- −The company has reported consistently negative net profits, such as -Rs 0.1371 Cr in Mar 2025.
- −Rekvina Laboratories Ltd. has a negative book value of Rs -2.03.
- −The Return on Capital Employed (ROCE) is significantly negative at -104.17%.
- −The profit margin is negative at -19.69%.
- −The company has been placed under surveillance measures including GSM and ESM, indicating regulatory scrutiny.
Financial Performance
Rekvina Laboratories Ltd. has reported fluctuating revenues over the last few years. Revenue was Rs 0 in Mar 2021, Mar 2022, Mar 2024, and Mar 2025. In Mar 2023, revenue was Rs 0.0038. Quarterly revenues have been reported as Rs 0.2 Cr in Sept 2025, Rs 0.35 Cr in Dec 2025, and Rs 0.72 Cr in Mar 2026. The company has consistently reported negative net profits, with -Rs 0.0642 Cr in Mar 2021, -Rs 0.078881001 Cr in Mar 2022, -Rs 0.0007 Cr in Mar 2023, -Rs 0.0164 Cr in Mar 2024, and -Rs 0.1371 Cr in Mar 2025.
Profitability & Returns
The company has a negative profit margin of -19.69%. Return on Capital Employed (ROCE) is significantly negative at -104.17%. While Return on Equity (ROE) is 20.74%, this figure should be considered in conjunction with the negative book value of Rs -2.03 and negative EPS of Rs -0.23 as of Mar 2025. Earnings Per Share (EPS) has been consistently negative, ranging from -Rs 0.001 in Mar 2023 to -Rs 0.23 in Mar 2025.
Balance Sheet
Rekvina Laboratories Ltd. has a negative book value of Rs -2.03. The company reports a debt-to-equity ratio of 0, indicating no debt. This could also suggest limited access to traditional financing or a lack of operations requiring significant debt. Further details on assets and liabilities are not available in the provided data.
Ownership & Pledges
As of March 31, 2026, the public shareholding in Rekvina Laboratories Ltd. stood at 58.70%, with promoter holding at 41.30%. There are no shares pledged by the promoters, with promoter pledge reported as 0. The number of shareholders as of March 31, 2026, is 2475.
Regulatory & Surveillance
Rekvina Laboratories Ltd. is currently subject to surveillance measures. The company is classified under GSM (Graded Surveillance Measure) and ESM (Enhanced Surveillance Measure), with specific levels indicated as 'GSM 0' and 'ESM 1'. These measures are implemented by exchanges to monitor securities with unusual price movements or trading activity, indicating potential risks.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.